Lincoln International’s Global Healthcare Group Announces Record Year

Lincoln International remains one of the most active healthcare M&A advisors in 2021

Lincoln International’s global healthcare mergers and acquisitions (M&A) activity in 2021 eclipsed that of 2020 led by the firm’s growing sector capabilities and strong appetite for deals. In 2021, we completed transactions with or on behalf of some of the largest and most well-known names in healthcare private equity. Lincoln’s reputation for advising on, executing and closing high-quality assignments across healthcare services, life sciences, pharma outsourcing, medical products and healthcare information technology (IT) continues to strengthen. Lincoln is one of the only investment banks with dedicated, senior healthcare bankers covering markets across the Americas, Europe and Asia.

Summary

  • Lincoln International's global Healthcare Group celebrates record results in 2021.

Select Notable 2021 Healthcare Transactions

Related Perspectives

PETS International | Consolidation Meets Regulation in the Veterinary Clinics Market

Originally posted by PETS International on April 5, 2024. Animal health is becoming a big business in Europe and the U.S. Thus, regulators are turning a closer eye to mergers… Read More

“Leader to Leader” Series

The Leader to Leader video series turns up the dial on rich conversations with prominent leaders – from business owners and entrepreneurs to investors and CEOs – highlighting their stories… Read More

What Price is Right? Trends and Opportunities for Private Equity in Pharma Market Access

The cost of developing new drugs is staggering. Among the top 20 global biopharmas, the average cost of developing a candidate from discovery through clinical trials to market was approximately… Read More

Investment Opportunities in Pharma: A Data-Driven Exploration of CDMO Appeal

The report discusses the current state of the contract development and manufacturing organization (CDMO) market within the pharmaceutical industry, emphasizing the increased interest from private equity (PE) investors. The pharmaceutical… Read More

Meet Our Senior Team